citizen science
Auto Added by WPeMatico
Auto Added by WPeMatico
The Borderlands series has long offered players a chaotic loot scramble of explosive cel-shaded cartoon violence and intricately tuned shooting that leaves anything that isn’t the fun part on the cutting room floor. It’s like the gaming equivalent of a very large, very rich dessert — and what if, by eating dessert, you could also make the world better? Imagine.
Borderlands 3 publisher 2K and developer Gearbox Software is elevating the series’ latest game to lofty new ideals with a new in-game experience called Borderlands Science, a crowdsourced citizen science project that will leverage the hit game’s massive player base to conduct actual scientific research. In this case that’s mapping the gut microbiome — one of the most interesting frontiers in biological science right now. Scientists believe that microbes in the gut could play a role in everything from autism to allergies, though many of those mechanics remain mysterious and difficult to study given the massive breadth of microbes in the gut and the limits of computational power.
For players, Borderlands Science appears in the game as a retro arcade cabinet that will pop up soon on Sanctuary III, the game’s central starship. The mini-game itself looks like a colorful, Tetris-like experience, and if players don’t read the fine print they might not even know that they’re mapping microbes. Assuming that Gearbox’s normal ethos is on display here it’s also likely fun and addictive, though we haven’t yet tried it. And of course, players won’t be expected to engage with the project for the good of science alone. The mini-game will offer players special rewards and Vault Hunter skins to collect — a smart and natural way to incentivize players in a game that’s all about the pursuit of loot.

The undertaking is a partnership between researchers at McGill University, the Microsetta Initiative at UC San Diego School of Medicine and Massively Multiplayer Online Science (MMOS), a project connecting video games with vital scientific research.
“We see Borderlands Science as an opportunity to use the enormous popularity of Borderlands 3 to advance social good,” Gearbox Software co-founder Randy Pitchford said of the initiative, calling it a “new nexus between entertainment and health.”
Gaming-focused citizen science is emerging as a fascinating way to pair the gaming community’s natural strengths — sustained focus, patience for repetitive tasks, intensive time commitments — with the needs of scientific researchers. Two prominent examples are EyeWire, which invites players to help map the brain’s neural networks and Foldit, in which users solve puzzles to map complex protein structures believed to have a role in diseases like HIV and Alzheimer’s.
Apart from a handful of exceptions — like EVE Online players mapping exoplanets — these citizen science games are usually browser-based, with more of an edu-science vibe than anything resembling the flashy hit games that drive the industry. Borderlands Science bridges that gap, bringing citizen science into the lucrative, bustling world of triple-A games. And if the model pioneered here goes well, the project could be an excellent example for other publishers and developers looking to weave real scientific good into their games in the future.
Powered by WPeMatico
The microbiome testing service uBiome has placed its founders and co-chief executives, Jessica Richman and Zac Apte, on administrative leave following an FBI raid on the company’s offices last week.
The company’s board of directors have named John Rakow, currently the company’s general counsel, as its interim chairman and chief executive, the company said in a statement.
Directors of the company are also conducting an independent investigation into the company’s billing practices, which is being overseen by a special committee of the board.
It was only last week that the FBI went to the company’s headquarters to search for documents related to an ongoing investigation. What’s at issue is the way that the company was billing insurers for the microbiome tests it was performing on customers.
“As interim CEO of uBiome, I want all of our stakeholders to know that we intend to cooperate fully with government authorities and private payors to satisfactorily resolve the questions that have been raised, and we will take any corrective actions that are needed to ensure we can become a stronger company better able to serve patients and healthcare providers,” Rakow said in a statement.
”My confidence is based on the significant clinical evidence and medical literature that demonstrates the utility and value of uBiome’s products as important tools for patients, health care providers and our commercial partners.” added Mr. Rakow.
It’s been a rough few weeks for consumer companies working on developing microbiome testing services and treatments based on those diagnosis. In addition to the FBI raid, the Seattle-based company, Arivale, was forced to shut down its “consumer program” after raising more than $50 million from investors, including Maveron, Polaris Partners and ARCH Venture Partners.
UBiome is backed by investors including Andreessen Horowitz, OS Fund, 8VC, Y Combinator, DNA Capital, Crunchfund, StartX, Kapor Capital, Starlight Ventures and 500 Startups.
Powered by WPeMatico
23andMe, IBM and now uBiome is the next tech company to jump into the lucrative multi-billion dollar drug discovery market.
The company started out with a consumer gut health test to check whether your intestines carry the right kind of bacteria for healthy digestion but has since expanded to include over 250,000 samples for everything from the microbes on your skin to vaginal health — the largest data set in the world for these types of samples, according to the company.
Founder Jessica Richman now says there’s a wider opportunity to use this data to create value in therapeutics.
To support its new drug discovery efforts, the San Francisco-based startup will be moving its therapeutics unit into new Cambridge, Massachusetts headquarters and appointing former Novartis CEO Joseph Jimenez to the board of directors as well.
The company has a healthy pile of cash to help build out that new HQ, too, with a fresh $83 million Series C, lead by OS Fund and in participation with 8VC, Y Combinator, Dentsu Ventures and others.
The drug discovery market is slated to be worth nearly $86 billion by 2022, according to BCC Research numbers. New technologies — those that solve logistics issues and shorten the time between research and getting a drug to market in particular — are driving the growth and that’s where uBiome thinks it can get into the game.
“This financing allows us to expand our product portfolio, increase our focus on patent assets and further raise our clinical profile, especially as we begin to focus on commercialization of drug discovery and development of our patent assets,” Richman said.
Though its unclear at this time which drug maker the company might partner up with, Richman did say there would be plenty to announce later on that front.
So far, the company has published over 30 peer-reviewed papers on microbiome research, has entered into research partnerships with the likes of the Center for Disease Control (CDC) and leading research institutions such as Harvard, MIT and Stanford and has previously raised $22 million in funding. The additional VC cash puts the total amount raised to $105 million to date.
Powered by WPeMatico
Back in February, seismologists at UC Berkeley released MyShake, an app that passively monitors for seismic activity, both watching for earthquakes and warning users if one is underway. In the months since its introduction, the app has outperformed its creators’ expectations, detecting over 200 earthquakes in more than ten countries. Read More
Powered by WPeMatico